BK vs LAB · P/E 17, rev $20.08B vs rev $174.4M
The Bank of New York Mellon Corporation (BK) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
BK currently screens at market cap $94.14B and trailing P/E 17.0. LAB currently screens at market cap $317.1M.
Not investment advice. Open the BK and LAB stock pages for the full models.
Not investment advice.